KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Share-based Compensation (2016 - 2025)

Ionis Pharmaceuticals has reported Share-based Compensation over the past 13 years, most recently at $43.3 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $43.3 million for Q4 2025, up 19.84% from a year ago — trailing twelve months through Dec 2025 was $133.9 million (up 2.82% YoY), and the annual figure for FY2025 was $133.9 million, up 2.82%.
  • Share-based Compensation for Q4 2025 was $43.3 million at Ionis Pharmaceuticals, up from $31.1 million in the prior quarter.
  • Over the last five years, Share-based Compensation for IONS hit a ceiling of $43.3 million in Q4 2025 and a floor of $22.3 million in Q4 2021.
  • Median Share-based Compensation over the past 5 years was $29.7 million (2025), compared with a mean of $29.5 million.
  • Biggest five-year swings in Share-based Compensation: plummeted 76.58% in 2021 and later surged 37.26% in 2024.
  • Ionis Pharmaceuticals' Share-based Compensation stood at $22.3 million in 2021, then grew by 15.41% to $25.7 million in 2022, then increased by 2.52% to $26.3 million in 2023, then skyrocketed by 37.26% to $36.1 million in 2024, then rose by 19.84% to $43.3 million in 2025.
  • The last three reported values for Share-based Compensation were $43.3 million (Q4 2025), $31.1 million (Q3 2025), and $29.7 million (Q2 2025) per Business Quant data.